Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

New Findings on Rheumatic Drug Therapies among Patients with Ankylosing Spondylitis, Gout, SLE

Thomas R. Collins  |  Issue: March 2017  |  March 20, 2017

A study shows no increased risk of chronic kidney disease from allopurinol use in newly diagnosed gout patients who start out with normal or near-normal kidney function.

A study shows no increased risk of chronic kidney disease from allopurinol use in newly diagnosed gout patients who start out with normal or near-normal kidney function.
crystal light/shutterstock.com

WASHINGTON, D.C.—Taking high-dose non-steroidal anti-inflammatory drugs (NSAIDs) with a TNF inhibitor as an ankylosing spondylitis (AS) patient is linked with a 61% decrease in the chances your disease will progress, suggesting there may be a synergy when the drugs are used together, according to a longitudinal observational study from researchers at the University of California, San Francisco (UCSF).

The findings were highlighted at the 2016 ACR/ARHP Annual Meeting in a Discovery abstract session that also included findings on allopurinol and chronic kidney disease in gout patients and the effects of poverty on SLE damage.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

NSAIDs & AS

TNF inhibitors and NSAIDs have shown mixed results in preventing AS progression. Researchers set out to gauge the benefit seen in those taking TNF inhibitors and NSAIDs together. They looked at 538 patients in the Prospective Study of Outcomes in Ankylosing Spondylitis, with patients followed for at least two years and a median of four. X-rays were collected every two years, with a determination of progression by mSASSS, the modified Stoke Ankylosing Spondylitis Spinal Score.

Among patients not exposed to NSAIDs or exposed only to low doses, there was no benefit in taking TNF inhibitors alone.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

But there was a significant benefit observed for those taking a high-dose NSAID along with an anti-TNF over those taking a high-dose NSAID but not an anti-TNF. The odds of progression were decreased by 61% for those taking both an anti-TNF and high-dose NSAIDs (P=0.04). Researchers found an interaction between the NSAID and TNF inhibitor use after adjusting propensity scores to address confounders introduced by the drugs’ indications.

“Another way to look at the estimated probability of progression by treatment group is to stratify it by TNF inhibitor use,” said Lianne Gensler, MD, director of the Ankylosing Spondylitis Clinic at UCSF. “When you look at the patients with high-dose NSAIDs, you can see that their estimated probability of progression is significantly lower when using TNF inhibitors—almost a 50% reduction in fact.”

‘Therapy for gout with allopurinol does not appear to have a harmful effect on renal function,’ Dr. Vargas-Santos said.

She said that this suggests a “synergistic effect” not seen when the therapies are used separately.

“I want to be clear that this is a longitudinal observational study and it does not prove causality,” Dr. Gensler said. “There are still unmeasured confounders that may possibly be playing a role.”

Asked whether she would now recommend that patients on TNF inhibitors automatically take continuous NSAIDs, she gave a firm “no.”

“I would love to see a randomized controlled trial to prove causality, but at the end of the day, we treat patients based on symptoms,” she said. “And if patients have absolutely no disease activity by symptoms on a TNF inhibitor, I would never tell them to add an NSAID.”

Allopurinal & Gout

In another study, researchers found that there was no increased risk of chronic kidney disease (CKD) of at least Stage 3 from the urate-lowering therapy allopurinol use in newly diagnosed gout patients who start out with normal or near-normal kidney function.2

Physicians are cautious about using allopurinol in patients with CKD, using lower dosing or not using it at all, and about 20% of people with gout have CKD. But data are limited for those with normal kidney function who take allopurinol.

Researchers examined data from The Health Improvement Network, a general practitioner electronic medical records database that is meant to represent the general U.K. population. Drawn from about 44,000 patients, 13,685 patients who began allopurinol during the study period were matched with 13,685 nonusers. The groups were similar demographically, in their comorbidities, in the other medications they were taking, and in lab data, said Ana Beatriz Vargas-Santos, MD, a rheumatologist who was a research fellow at Boston University School of Medicine.

Among the allopurinol users over an average follow-up of four years, there were 1,384 cases of CKD Stage 3 or higher, and 1,372 among the allopurinol nonusers, a difference that was not significant (hazards ratio 0.99, 95% CI 0.92–1.07).

“This is an important message for healthcare providers, highlighting that therapy for gout with allopurinol does not appear to have a harmful effect on renal function,” Dr. Vargas-Santos said.

Financial Impact on Disease

Researchers at UCSF found that SLE patients who were poor from 2003 through 2009 accrued more disease damage through 2015 than those patients who were not poor.3 Most of the difference came from patients with the highest “dose” of poverty, with patients poor during the entire period accruing twice as much damage as those who were never poor. The differences were not as stark between those were never poor and those who were poor during only some of those years, suggesting that withdrawal from poverty could improve results.

“The relationship between poverty and damage accrual meets epidemiological criteria for plausibility based on dose-response and withdrawal of exposure,” said Edward Yelin, PhD, professor in residence of medicine and health policy at UCSF. “The next steps are to explore why poverty may lead to increased levels of damage accrual.”

Living in areas of concentrated poverty, as well as stress levels, could be two mechanisms involved, he said. Researchers found that there was a significant difference in SLE damage accrual between those who were poor living in areas of concentrated poverty and poor patients not living in areas of concentrated poverty. Being poor and reporting high stress also was linked to higher damage accrual, they found. Furthermore, those living in poverty are about twice as likely to experience high levels of stress—66% to 37%.

“Reducing damage in lupus may require efforts to reduce the stresses associated with poverty,” Dr. Yelin said. “For example, advocating for an increased level of economic assistance and social services, including means to leave areas of concentrated poverty through housing vouchers.”


Thomas Collins is a freelance medical writer based in Florida.

Miss Any of These Important Sessions?

If you missed any of these important sessions, find them on SessionSelect.

References

  1. Gensler L, Reveille J, Lee M, et al. High dose nonsteroidal anti-inflammatory drugs (NSAIDs) and tumor necrosis factor inhibitor use results in less radiographic progression in ankylosing spondylitis—a longitudinal analysis [abstract 1956]. Arthritis Rheumatol. 2016;68(suppl 10).
  2. Vargas-Santos AB, Peloquin C, Zhang Y, et al. No increased risk of chronic kidney disease with allopurinol use [abstract 1957]. Arthritis Rheumatol. 2016;68(suppl 10).
  3. Yelin E, Yazdany J, Trupin L. Effect of poverty status in 2009, % of year in poverty between 2003 and 2009, and existing poverty permanently by 2009 on SLE damage in 2015 [abstract 1958]. Arthritis Rheumatol. 2016;68(suppl 10).

Page: 1 2 3 | Multi-Page
Share: 

Filed under:Axial SpondyloarthritisConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:2016 ACR/ARHP Annual MeetingAllopurinolAmerican College of Rheumatology (ACR)Ankylosing SpondylitisGoutnonsteroidal anti-inflammatory drugsNSAIDoutcomepatient careRheumatic DiseaserheumatologistrheumatologySLESystemic lupus erythematosus

Related Articles

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    New Studies Examine Impact of Poverty, Race, Ethnicity in Patients with SLE

    October 17, 2017

    mantinov / shutterstock.com To correctly address a problem, one must have a handle on its nuances—a clear understanding of what is linked and how. And thus far, when it comes to lupus, we haven’t reached the point of understanding those intricacies. Things are heading in the right direction, however, with two new studies that get…

    Blacks, Asians at Higher Risk for Allopurinol-Related Skin Reactions

    September 8, 2016

    Blend Images/shutterstock.com Be careful when prescribing allo­purinol to black and Asian gout patients, a study newly advises. Black and Asian patients who take this ubiquitous, more-than-40-year-old medication are at much higher risk of certain serious skin reactions than are Caucasians or Hispanics. Compared with Caucasians, blacks who take allopurinol to lower blood urate levels have…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences